WITEPSOL W 35

$0.00

Hard fat, Adeps solidus

Product Application: Capsule filling,Chewable Tablet,Implants,Microencapsulation,Ovule,SLN Processes,Suppository,Tablet
Product Certification: GMP,Halal,OU Kosher
Pharmaceutical Category: Solid triglycerides

WITEPSOL W 35 quantity

Request Sample Download Product BrochureDownload Product Spec Sheet

WITEPSOL W 35 is from the W grade of hard fats with hydroxyl values between 20–50. They comprise of mixture of 65–80% of triglycerides, 10–35% of diglycerides and 1–5 % of monoglycerides. Correspondingly they have a wider gap between melting and solidification temperatures and are therefore more insensitive (elastic) to shock cooling. They solidify more slowly. The amount of partial glycerides delays the sedimentation of solid active ingredients and promotes wetting of mucous membranes.

WITEPSOL W 35 has a hydroxyl value of 40-50.

Hard fat recommendations for commonly used active pharmaceutical ingredients:

• Actives for malaria treatment
• Anesthetics
• Anti-inflammatory substances
• Antidepressants (alkaloids)
• Antimetics
• Antiepileptics (barbiturates)
• B vitamins
• β-lactam antibiotics
• Bronchodilatators
• Expectorants
• Male hormones
• Nonsteroidal anti-inflammatory drugs
• Steroidal antirheumatics (corticosteroids)

Melting Point (°C): ~34

Molten WITEPSOL® behaves approximately like a Newtonian liquid; the measured shear stress is almost linearly dependent on the applied shear rate. The viscosity is lower for the H grades then for the partial glycerides containing W grades, like WITEPSOL W 35. S grades have a slightly higher viscosity due to the emulsifier content:

Comparison of the rheological behavior of pure WITEPSOL® grades:

 

 

 

 

 

 

Viscosities as a function of temperature for suppository bases, exhibiting an open-tube melting point of:

 

 

 

 

 

 

 

WITEPSOL® H 15 contains – besides triglycerides (C36–C54) – monoglycerides (< 1%) and about 10% of diglycerides, corresponding to a hydroxyl value of about 10. Higher hydroxyl values can be expected due to higher amounts of diglycerides (for example WITEPSOL W 35) or additionally by means of an increased proportion of monoglycerides (for example WITEPSOL W 45).